Nectar Lifesciences Ltd, a leading pharmaceutical manufacturer headquartered in Chandigarh, conducted its 2025–26/01st Extraordinary General Meeting (EGM) on August 4, 2025, at its Registered Office in Village Saidpura, Tehsil Dera Bassi, Punjab. The meeting commenced at 10:00 A.M., with members and directors participating in key strategic decisions regarding management changes and business restructuring.

The meeting was chaired by Dr. Surulichamy Senthilkumar, Director (R&D), who was also formally introduced and proposed for appointment as a director during the meeting.

Key Highlights of the EGM:

The quorum required under Section 103 of the Companies Act, 2013, and the Company’s Articles of Association was met, and the meeting was declared in order by the Chairman.

The company had provided shareholders with remote e-voting from August 1 to August 3, 2025, and also arranged physical ballot voting at the meeting venue. Mr. Prince Chadha, Proprietor of M/s P. Chadha & Associates, was appointed as the Scrutinizer to oversee the fair and transparent voting process.

The following resolutions were placed before the shareholders under special business, and voting took place through the prescribed methods:

1. Appointment of Dr. Surulichamy Senthilkumar as Director

• Type: Ordinary Resolution

• Details: Approved appointment of Dr. Surulichamy Senthilkumar as a Director liable to retire by rotation. This decision brings formal board-level recognition to his role, acknowledging his contribution to the company’s R&D initiatives.

2. Appointment as Wholetime Director (R&D)

• Type: Special Resolution

• Details: Approved appointment of Dr. Surulichamy Senthilkumar as a Wholetime Director designated as Director (R&D) for a term of three years. His leadership is expected to drive innovation and research across APIs and formulations.

3. Approval of Slump Sale to Ceph Lifesciences Pvt. Ltd.

• Type: Special Resolution

• Details: The Board obtained shareholder approval for the transfer of the company’s business to Ceph Lifesciences Private Limited, a related entity, on a going concern basis through a slump sale. The transaction aims to restructure operations and improve business focus.

Transparent Voting Process

Ballot boxes were provided at the meeting for physical polling. After voting concluded, the boxes were sealed and taken into custody by the scrutinizer. Results of voting—covering both remote e-voting and physical ballots—will be compiled and disclosed to BSE, NSE, and uploaded on the websites of Nectar Lifesciences and KFin Technologies, in accordance with Regulation 44(3) of SEBI LODR Regulations, 2015.

Closing Remarks by the Chairman

Dr. Senthilkumar, acting on behalf of the Board, thanked all shareholders and employees for their support and commitment to the company’s vision. He acknowledged the trust reposed by stakeholders, especially amid strategic transitions and ongoing operational changes.

Strategic Outlook

The slump sale to Ceph Lifesciences is seen as a strategic move to streamline Nectar Lifesciences’ operations, possibly separating business verticals for better capital allocation and efficiency. Ceph Lifesciences, a private entity, is likely to carry forward the operational legacy while enabling Nectar to pursue focused growth in other areas or prepare for possible M&A activities.

Company Background

Nectar Lifesciences Ltd (CIN: L24232PB1995PLC016664) is a vertically integrated pharmaceutical company engaged in manufacturing and marketing of APIs (Active Pharmaceutical Ingredients), intermediates, and finished dosage forms. It is also a prominent exporter and holds certifications from major global health authorities.

Headquartered in Chandigarh, with manufacturing in Dera Bassi, Punjab, Nectar Lifesciences serves clients across Europe, South Asia, and Latin America, and is listed on both BSE (Scrip Code: 532649) and NSE

.

The Upcoming IPOs in this week and coming weeks are ConnPlex Cinemas, ALL Time Plastics, JSW Cement, Sawaliya Foods Products, ANB Metal Cast, Highway Infrastructure.

The Current active IPO are Parth Electricals & Engineering, Jyoti Global Plast, Essex Marine, Aaradhya Disposal Industries, BLT Logistics, Bhadora Industries, Flysbs Aviation, Cash Ur Drive Marketing, Renol Polychem.

Start your Stock Market Journey and Apply in IPO by Opening Free Demat Account in Choice Broking FinX.

Join our Trading with CA Abhay Telegram Channel for regular Stock Market Trading and Investment Calls by CA Abhay Varn - SEBI Registered Research Analyst.